New pharmacologic approaches to acute spinal cord injury

Pharmacotherapy

Volumn 16, Issue 3 I, 1996, Pages 382-392

  Rhoney, Denise H ^a   Luer, Mark S ^b   Hughes, Melody ^c   Hatten, Jimmi ^c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11ALPHA,17,21 TRIHYDROXYPREGNA 1,4 DIENE 3,20 DIONE 21 HYDROGEN SUCCINATE 11 TEBUTATE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 21 [4 [5,6 BIS(DIETHYLAMINO) 2 PYRIDYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,4,9(11) TRIENE 3,20 DIONE; 21 AMINOSTEROID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZETIRELIN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; DEXTRORPHAN; DIZOCILPINE; GANGLIOSIDE GM1; GROWTH FACTOR; METHYLPREDNISOLONE; MONTIRELIN; N METHYL DEXTRO ASPARTIC ACID; NALOXONE; NEUROPROTECTIVE AGENT; NIMODIPINE; OPIATE ANTAGONIST; OROTIRELIN; PROTIRELIN; PROTIRELIN DERIVATIVE; SCAVENGER; TIRILAZAD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVIEW; SPINAL CORD INJURY; VITAMIN INTAKE;

ANTIOXIDANTS; GANGLIOSIDES; HUMANS; NARCOTIC ANTAGONISTS; NEUROPROTECTIVE AGENTS; SPINAL CORD INJURIES; THYROTROPIN-RELEASING HORMONE;

EID: 0029978572     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Green BA, Klose JK, Goldberg ML. Clinical and research considerations in spinal cord injury. In: Becker DP, Povlishock JT, eds. Central nervous system trauma status report. Washington, DC: National Institutes of Health, 1985:341-68.
2. Fine PR, Devivo ME, Stovers S, et al. The state of the national spinal cord injury' database. Paraplegia 1987;24:51-2.
3. Tator CH. Spine-spinal cord relationships in spinal cord trauma. Clin Neurosurg 1983;30:479-94.
4. Nolle J. Spinal cord. In: Nolte J, ed. The human brain: an introduction to its functional anatomy. St. Louis: Mosby-Year Book, 1993:119-53.
5. deGroot J. The spinal cord. In: deGroot J, ed. Correlative neuroanalomy. Norwalk, CT: Appleton & Lange, 1991:27-54.
6. Janssen L, Hanseboul RR. Pathogenesis of spinal cord injury and newer trealments. Spine 1989;14:23-32.
7. Horlocker TT, Cucchiara RF, Ebersold MJ. Veterbral column and spinal cord surgery. In: Cucchiara RF, Michenfelder JD, eds. Clinical neuroaneslhesia. New York: Churchill Livingsione, 1990:325-50.
8. Mickey R, Albin MS, Bunegin L, Gelineau J. Autoregulation of spinal cord blood flow: is the cord a microcosm of the brain? Stroke 1986;17:1183-9.
9. Anderson DK, Hall ED. Pathophysiology of spinal cord trauma. Ann Emerg Med 1993;22:987-92.
10. Luer MS, Rhoney DH, Hughes M, Hatton J. New pharmacologie strategies in acute neuronal injury. Pharmacotherapy In press.
11. Tator CH, Fehlings MG. Review of ihe secondary injury iheory of acule spinal cord trauma wilh emphasis on vascular mechanism. J Neurosurg 1991;75:15-26.
12. Young W. Secondary injury mechanisms in acute spinal cord injury. J Emerg Med 1993;11:13-22.
13. Faden AI, Salzman S. Pharmacological strategies in CNS trauma. TIPS 1992;13:29-35.
14. Anderson DK, Waters TR, Means ED. Pretreaiment with alpha tocopherol enhances neurologic recovery afler experimental spinal cord compression injury. J Neurotrauma 1988;5(1):61-7.
15. Machlin LJ, Gabriel E. Kinetics of tissue alpha-tocopherol uptake and depletion after administration of high levels of vitamin E. NY Acad Sci 1982;393:48-59.
16. Taoka Y, Ikata T, Fukuzawa K. Influence of dietary vitamin E deficiency on compression injury of rat spinal cord. J Nutr Sci Vitaminol 1990;36:217-26.
17. Hall ED, Braughler JM. Role of lipid peroxidation in posttraumatic spinal cord degeneration: a review. CNS Trauma 1987;3:281-93.
18. Braughler JM. Lipid peroxidation-induced inhibition of gamma-aminobutyric acid uptake in rat brain synaptosomes: protection by glucocorlicoids. J Neurochem 1985;44:1282-8.
19. Hall ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg 1992;76:13-22.
20. Hall ED, Wolf DL, Braughler JM. Effects of a single large dose of methylprednisolone sodium succinate on experimental posttraumatic spinal cord ischemia: dose-response and time-action analysis. J Neurosurg 1984;61:124-30.
21. Bracken MB, Collins WE, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984;251:45-52.
22. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the second national acute spinal cord injury study. N Engl J Med 1990;322:1405-11.
23. Bracken MB, Shepard MJ, Hellenbrand KG, et al. Methylprednisolone and neurological function 1 year after spinal cord injury: results of the national acute spinal cord injury study. J Neurosurg 1985;63:704-13.
24. Bracken MB, Holford TR. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg 1993;79:500-7.
25. Bracken MB. Pharmacological treatment of acute spinal cord injury: current status and future projects. J Emerg Med 1993;11:43-6.
26. Galandiuk S, Rague G, Appel S, Polk HC. The two-edged sword of large-dose steroids for spinal cord trauma. Ann Surg 1993;218:419-25.
27. Hall ED, McCall JM, Chase RL, Yonkers PA, Braughler JM. A nonglucocorticoid steroid analog of methylprednisolone duplicates its high-dose pharmacology in models of central nervous system trauma and neuronal membrane damage. J Pharm Exp Ther 1987;242:137-42.
28. Hall ED, Yonkers PA, Andrus PK, Cox JW, Anderson DK. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma 1992;9(suppl 2):S425-42.
29. Anderson DK, Braughler JM, Hall ED, et al. Effects of treatment with U-74006F on neurological outcome after experimental spinal cord injury. J Neurosurg 1988;69:562-7.
30. Hall ED. Effects of the 21-aminosteroid U74006F on posttraumatic spinal cord ischemia in cats. J Neurosurg 1988;68:462-5.
31. Faden AI, Jacobs TP, Mougey E, Holaday JW. Endorphins in experimental spinal injury: therapeutic effect of naloxone. Ann Neurol 1981;10:326-32.
32. Flamm ES, Young W, Demopoulos HB, DeCrescito V, Tomasula JJ. Experimental spinal cord injury: treatment with naloxone. Neurosurgery 1982;10:227-31.
33. Young W, Flamm ES, Demopoulos HB, Tomasula JJ, DeCrescito V. Effect of naloxone on posttraumatic ischemia in experimental spinal contusion. J Neurosurg 1981;55:209-19.
34. Faden AI, Jacobs TP, Holaday JW. Comparison of early and late naloxone treatment in experimental spinal injury. Neurology 1982;32:677-81.
35. Wallace MC, Tator CH. Failure of naloxone to improve spinal cord blood flow and cardiac output after spinal cord injury. Neurosurgery 1986;18:428-32.
36. Flamm ES, Young W, Collins WF, et al. A phase 1 trial of naloxone treatment in acute spinal cord injury. J Neurosurg 1985;63:390-7.
37. Krumins SA, Faden AI. Traumatic injury alters opiate receptor binding in spinal cord. Ann Neurol 1986;19:498-501.
38. Faden AI, Jacobs TP. Dynorphin induces partially reversible paraplegia in the rat. Curr J Pharmacol 1983;91:321-4.
39. Faden AI, Takemori AE, Portoghese PS. κ-selective opiate antagonist nor-binaltorphimine improves outcome after traumatic spinal cord injury in rats. CNS Trauma 1987;4:227-37.
40. Skaper SD, Leon A. Monosialogangliosides, neuroprotection, and neuronal repair processes. J Neurotrauma 1992;9(suppl 2):S507-16.
41. Nicoletti F, Cavallaro S, Bruno V, et al. Gangliosides attenuate NMDA receptor-mediated excitatory amino acid release in cultured cerebellar neurons. Neuropharmacology 1989;28:1283-6.
42. Magel E, Louis JC, Aguilera J, Yavin E. Gangliosides prevent ischemia-induced down-regulation of protein kinase C in fetal rat brain. J Neurochem 1990;55:2126-31.
43. Gorio A, Ferrari G, Fusco M, et al. Gangliosides and their effects on rearranging peripheral and central neural pathways. CNS Trama 1984;1:29-37.
44. Gorio A. Ganglioside enhancement of neuronal differentiation, plasticity, and repair. CRC Crit Rev Clin Neurobiol 1986;2:241-96.
45. Sabel BA, Dunbar GL, Stein DG. Gangliosides minimize behavioral deficits and enhance structural repair after brain injury. J Neurosci Res 1984;12:429-43.
46. Geisler FH, Dorsey FC, Coleman WP. Recovery of motor function after spinal-cord injury - a randomized, placebocontrolled trial with GM-1 ganglioside. N Engl J Med 1991;324:1829-38.
47. Yarbrough GG. On the neuropharmacology of thyrotropin releasing hormone (TRH). Prog Neurobiol 1979;12:291-312.
48. Holaday JW, Tweng LF, Loh HH, Li CH. Thyrotropin releasing hormone antagonizes β endorphin hypothermia and catalepsy. Life Sci 1978;22:1537-43.
49. Tache Y, Lis M, Collu R. Effects of thyrotropin-releasing hormone on behavioral and hormonal changes induced by β-endorphin. Life Sci 1977;21:841-6.
50. Faden AI, Holaday JW. Naloxone treatment of endotoxin shock: stereospecificity of physiologic and pharmacologic effects in the rat. J Pharmacol Exp Ther 1980;212:441-7.
51. Faden AI, Hill TG, Kubek MJ. Changes in TRH immunoreactivity in spinal cord after experimental spinal injury. Neuropeptides 1986;7:11-18.
52. Salzman SK, Knight PB, Hirofuji E, el al. Spinal cord immunoreactive TRH is altered after local traumatic injury. Peptides 1987;8:247-50.
53. Faden AI, Jacobs TP, Smith MT, Holaday JW. Comparison of thyrotropin-releasing hormone (TRH), naloxone, and dexamethasone treatments in experimental spinal injury. Neurology 1983;33:673-8.
54. Faden AI, Jacobs TP, Holaday JW. Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N Engl J Med 1981;305:1063-7.
55. Arias MJ. Treatment of experimental spinal cord injury with TRH, naloxone, and dexamethasone. Surg Neurol 1987;28:335-8.
56. Faden AI, Jacobs TP, Smith MT. Thyrotropin-releasing hormone in experimental spinal injury: dose response and late treatment. Neurology 1984;34:1280-4.
57. Faden AI, Jacobs TP. Effects of TRH analogs on neurologic recovery after experimental spinal trauma. Neurology 1985;35:1331-4.
58. Faden AI. TRH analog YM-14673 improves outcome after traumatic brain and spinal cord injury in rats: dose-response studies. Brain Res 1989;486:228-35.
59. Faden AI. Pharmacotherapy in spinal cord injury: a critical review of recent developments. Clin Neuropharmacol 1987;10:193-204.
60. Rogawski MA. The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs 1992;44:279-92.
61. Faden AI, Simon RP. A potential role for excitotoxins in the pathophysiology of spinal cord injury. Ann Neurol 1988;23:623-7.
62. Albers GW. Potential therapeutic uses of N-methyl-D-aspartate antagonists in cerebral ischemia. Clin Neuropharmacol 1990;13:177-97.
63. Faden AI, Ellison JA, Noble LJ. Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur J Pharmacol 1990;175:165-74.
64. Faden AI, Lemke M, Simon RP, Nobel LJ. N-Methyl-D-aspartate antagonist MK801 improves outcome after traumatic spinal cord injury in rats: behavioral, anatomic, and neurochemical studies. J Neurotrauma 1988;5:33-45.
65. Gomez-Pinilla F, Tram H, Cotman CW, Nieto-Sampedro M. Neuroprotective effect of MK-801 and U-50488H after contusive spinal cord injury. Exp Neurol 1989;104:118-24.
66. Hall ED, Wolf DL. A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal cord ischemia.] Neurosurg 1986;64:951-61.
67. Kazda S, Towart R. Nimodipine: a new calcium antagonistic drug with a preferential cerebrovascular action. Acta Neurochir 1982;63:259-65.
68. Haghighi SS, Stiens T, Oro JJ, Madsen R. Evaluation of the calcium channel antagonist nimodipine after experimental spinal cord injury. Surg Neurol 1993;39:403-8.
69. Faden AI, Jacobs TP, Smith MT. Evaluation of the calcium channel antagonist nimodipine in experimental spinal cord ischemia. J Neurosurg 1984;60:796-9.
70. Ford RWJ, Malm DN. Failure of nimodipine to reverse acute experimental spinal cord injury. CNS Trauma 1985;2:9-17.
71. Guha AB, Tator CH, Piper I. Increase in rat spinal cord blood flow with the calcium channel blocker, nimodipine. J Neurosurg 1985;63:250-9.
72. Lefer AM. Eicosanoids as mediators of ischemia and shock. Fed Proc 1985;44:275-80.
73. Jonsson HT, Daniell HB. Altered levels of PGF in cat spinal cord tissue after traumatic injury. Prostaglandins 1976;11:51-9.
74. Hsu CY, Halushka PV, Hogan EL, et al. Alteration of thromboxane and prostacyclin levels in experimental spinal cord injury. Neurology 1985;35:1003-9.
75. Faden AI, Chan PH, Longar S. Alterations in lipid metabolism, Na, K-ATPase activity and tissue water content of spinal cord after experimental traumatic injury. J Neurochem 1987;48:1809-1916.
76. HallenbeckJM, Jacobs TP, Faden AI. Combined PGI2, indotnethacin, and heparin improves neurological recovery after spinal trauma in cats. J Neurosurg 1983;58:749-54.
77. Shetty KR, Sutton CH, Mattson DE, Rudman D. Hyposomatomedinemia in quadriplegic men. Am J Med Sci 1993;305(2):95-100.
78. Koshinaga M, Sanan HR, Whittemore SR. Altered acidic and basic fibroblast growth factor expression after spinal cord injury. Exp Neurol 1993;120(1):32-48.
79. O'Hara CM, Chemoff EA. Growth factor modulation of injury-reactive ependymal cell proliferation and migration. Tissue Cell 1994;26(4):599-611.
80. Fernandez E, Pallini R, Lauretti L, et al. Spinal cord transection in adult rats: effects of local infusion of nerve growth factor on the corticospinal tract axons. Neurosurgery 1993;33(5):889-93.
81. Schnell L, Schneider R, Kolbeck R, Barde YA, Schwab ME. Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion. Nature 1994;367(6459):170-3
82. Hiraizumi Y, Transfeldt EE, Kawahara N, et al. The effect of growth factor formula (platelet derived wound healing formula) in experimental spinal cord injuries. J Am Paraplegia Soc 1992;15(1):7-13.